Bristol-Myers Squibb Company (BMY) Stock

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Bristol-Myers Squibb Company is led by CEO Christopher S. Boerner, employs 34,100 people, headquartered in Princeton, US, publicly traded since 1972.

Bristol-Myers Squibb Company (BMY) stock trades at $63.10 with a market capitalization of $128.85B. The stock is valued at a price-to-earnings (P/E) ratio of 15.73, price-to-book of 5.71, price-to-sales of 2.36. Over the past 52 weeks the stock has ranged between $42.52 and $63.92, and currently trades 1.3% below its 52-week high. It pays a dividend yielding 4.47%.

On profitability, Bristol-Myers Squibb Company generates a return on equity (ROE) of 38.73% — well above the market average, a sign of a high-quality business, return on capital employed of 68.60%, an operating margin of 26.34%, a net profit margin of 15.01%.

In its most recent fiscal year, Bristol-Myers Squibb Company reported annual revenue of $48.2B, net profit of $7.1B, revenue has compounded at 2.5% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 2.22 — a leveraged balance sheet worth monitoring, a current ratio of 1.26, total assets of $90.0B, $10.2B in cash and equivalents.

BMY has an average daily trading volume of 12,006,173 shares, a beta of 0.24 (less volatile than the overall market).

Official website: www.bms.com